Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06525220 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
A Phase 3 study of Head and Neck Squamous Cell Carcinoma, sponsored by Merus B.V..
- Recruiting
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
- 20
- Study locations
NCT06525220 is a Phase 3 study of Head and Neck Squamous Cell Carcinoma that is actively recruiting participants, run by Merus B.V.. The registered enrollment target is 500 participants, above the 113-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (342% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT06525220, a Phase 3 study of Head and Neck Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Merus B.V..
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Petosemtamab
Study Locations (20)
Florida
- Site 14 - Fort Myers
- Site 48 - Orlando
- Site 8 - Orlando
- Site 21 - St. Petersburg
- Site 20 - West Palm Beach
California
- Site 36 - La Jolla
- Site 27 - Los Angeles
- Site 16 - Palo Alto
Alabama
- Site 164 - Mobile
Delaware
- Site 19 - Newark
District of Columbia
- Site 108 - Washington D.C.
Georgia
- Site 171 - Atlanta
Illinois
- Site 50 - Chicago
Kentucky
- Site 2 - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2024-09-25 |
| Est. Completion | 2030-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06525220
The ClinicalTrials.gov registry entry for NCT06525220 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 113-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (342% higher). The listed sponsor is Merus B.V., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Head and Neck Squamous Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06525220 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT06525220 about?
NCT06525220 is a clinical study titled "A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)". This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
What is the current status of trial NCT06525220?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2024-09-25. Estimated completion is 2030-07.
What conditions does trial NCT06525220 study?
This clinical trial studies the following conditions: Head and Neck Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06525220?
The interventions under investigation include: Pembrolizumab (DRUG), Petosemtamab (DRUG).
Who is sponsoring clinical trial NCT06525220?
This trial is sponsored by Merus B.V., which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06525220 being conducted?
This trial has 20 study locations across Alabama, California, Delaware, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
RECRUITING · Phase 3
-
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
RECRUITING · Phase 3
-
3D Specimen Maps for RT Planning
RECRUITING
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.